Adial Pharmaceuticals

Yahoo Finance • last month

Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

GLEN ALLEN, Va., March 06, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of ad... Full story

Yahoo Finance • 2 months ago

Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04

GLEN ALLEN, Va., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addi... Full story

Yahoo Finance • 2 months ago

Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement

Adial Pharmaceuticals, Inc Common Stock Will Begin Trading on Split-Adjusted Basis on February 6, 2026 GLEN ALLEN, Va., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-s... Full story

Yahoo Finance • 5 months ago

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds

GLEN ALLEN, Va., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addi... Full story

Yahoo Finance • 6 months ago

Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show

GLEN ALLEN, Va., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addi... Full story

Yahoo Finance • 6 months ago

Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution

GLEN ALLEN, Va., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addi... Full story

Yahoo Finance • 6 months ago

CoreWeave initiated, Instacart downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Morgan Stanley upgraded Celsius Holdin... Full story

Yahoo Finance • 8 months ago

Adial Pharmaceuticals reports Q2 results

* Adial Pharmaceuticals press release [https://seekingalpha.com/pr/20201045-adial-pharmaceuticals-reports-second-quarter-2025-financial-results-and-provides-business] (NASDAQ:ADIL [https://seekingalpha.com/symbol/ADIL]): Q2 net Loss was $... Full story

Yahoo Finance • 8 months ago

Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

GLEN ALLEN, Va., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addi... Full story

Yahoo Finance • 8 months ago

What's going on in today's pre-market session

Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. [premarket] GAINERS TICKER CHANGE COMMENT PBM [https://www.chartmill.com/stock... Full story

Yahoo Finance • 8 months ago

Curious about the stocks that are showing activity after the closing bell on Monday?

As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. [postmarket] AFTER HOURS GAINERS TICKER CHANGE... Full story

Yahoo Finance • 9 months ago

Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders’ Equity Listing Requirement

GLEN ALLEN, Va., July 16, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addi... Full story

Yahoo Finance • 9 months ago

Thermo Fisher Scientific (TMO) Inks Deal to Manufacture Adial Pharmaceuticals ADO4

Thermo Fisher Scientific Inc. (NYSE:TMO) is one of Goldman Sachs’ top healthcare stock picks. On June 25, the company confirmed it had inked a strategic partnership with Adial Pharmaceuticals (NASDAQ:ADIL).Thermo Fisher Scientific (TMO) In... Full story

Yahoo Finance • 9 months ago

Adial Pharmaceuticals files patent update for alcohol disorder treatment

GLEN ALLEN, Va. - Adial Pharmaceuticals, Inc. (NASDAQ:ADIL), a micro-cap pharmaceutical company with a market capitalization of $5 million, announced on Wednesday it has filed an update to its provisional patent application for AD04, the c... Full story

Yahoo Finance • 9 months ago

Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045

GLEN ALLEN, Va., July 09, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addi... Full story

Yahoo Finance • 9 months ago

Alcohol Use Disorder Market Report 2025-2035 Featuring Clearmind Medicine, Purdue Pharma, Psyence Biomedical, Eli Lilly and Co, Tempero Bio,, Nxera Pharma, Novo Nordisk, Adial, Alkermes, Lundbeck

Company Logo The global alcohol use disorder market is experiencing significant growth, driven by increasing demand for innovative and personalized treatments, and the integration of digital health technologies. Advancements in pharmacoth... Full story

Yahoo Finance • 10 months ago

Adial signs manufacturing deals for alcohol disorder drug trials

GLEN ALLEN, Va. - Adial Pharmaceuticals, Inc. (NASDAQ:ADIL), a micro-cap pharmaceutical company with a market capitalization of $3.62 million, has secured manufacturing agreements with Thermo Fisher Scientific and Cambrex to produce its in... Full story

Yahoo Finance • 10 months ago

Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply

Scope of Agreement with Cambrex to Provide Ondansetron HCL Drug Substance Under FDA Approved Drug Master File Scope Of Agreement With Thermo Fisher to Provide Manufacturing Services Including Demonstration, Clinical, Registration And Vali... Full story

Yahoo Finance • 10 months ago

Adial Pharmaceuticals announces pricing of $3.6M public offering

* Adial Pharmaceuticals (NASDAQ:ADIL [https://seekingalpha.com/symbol/ADIL]) on Tuesday announced the pricing of its public offering for the purchase and sale of 11.1M shares of common stock of the company, together with Series D warrant... Full story

Yahoo Finance • 10 months ago

Adial Pharmaceuticals files to register resale of 6.7M shares from warrant conversions

* Adial Pharmaceuticals (NASDAQ:ADIL [https://seekingalpha.com/symbol/ADIL]) is registering up to 6.73M shares of common stock for resale by certain selling stockholders. * The shares include over 6.5M issuable from Series B-1 and C-1... Full story